Mibeaz Drug Interactions

Bezafibrate: Bezafibrate may enhance the adverse/toxic effect of ezetimibe. Avoid combination.
Bile acid sequestrants: Bile acid sequestrants may decrease the absorption of ezetimibe. Ezetimibe should be administered at least 2 hours before or at least 4 hours after administration of the bile acid sequestrant.
Cyclosporine (systemic): Ezetimibe may increase the serum concentration of cyclosporine (systemic). Cyclosporine (systemic) may increase the serum concentration of ezetimibe. Patient receiving both drugs should be carefully monitored.
Fenofibrate and derivatives: Fenofibrate and derivatives increased ezetimibe concentrations and may enhance the adverse/toxic effect of ezetimibe. Specially, the risk of myopathy and cholelithiasis may be increased. When used in combination with fenofibrate, monitor liver function tests and signs and symptoms of cholelithiasis.
Gemfibrozil: Gemfibrozil may enhance the adverse/toxic effect of ezetimibe. Specifically, the risk of myopathy and cholelithiasis may be increased. Gemfibrozil may increase the serum concentration of ezetimibe. Avoid concomitant use of ezetimibe with gemfibrozil.
Antacids: Concomitant use of ezetimibe and an aluminum and magnesium hydroxide containing antacids decrease AUC and peak plasma concentration of total ezetimibe.
Hydroxymethylglutaryl-Coenzyme A (HMG-CoA) reductase inhibitors (statins): Concomitant use of ezetimibe and statins (atorvastatin, fluvastatin, lovastatin, pravastatin or rosuvastatin) decrease AUC of total ezetimibe and increase peak plasma concentration of total ezetimibe.
Warfarin: Increase international normalized ratio (INR) with concomitant use of ezetimibe and warfarin. If ezetimibe is initiated in a patient receiving warfarin, the INR should be monitored.